Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Zhang, Chris Zhiyi ^a   Pan, Yinghua ^b   Cao, Yun ^a   Lai, Paul B S ^c   Liu, Lili ^a   Chen, George Gong ^c   Yun, Jingping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; DIHYDROARTEMISININ; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN MCL 1; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; ARTEMISININS; CELL LINE, TUMOR; CYTOCHROMES C; DRUG SYNERGISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

MUS MUSCULUS;

EID: 84863004652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039870     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Erichsen R, Jepsen P, Jacobsen J, Norgaard M, Vilstrup H, et al. (2008) Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol 20: 104-110.
3. Bosch FX, Ribes J, Diaz M, Cleries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
4. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, et al. (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469.
5. Breous E, Thimme R, (2011) Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 54: 830-834.
6. Tsochatzis EA, Germani G, Burroughs AK, (2010) Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 37: 89-93.
7. Lane AA, Chabner BA, (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468.
8. Marks PA, Xu WS, (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608.
9. Prince HM, Bishton MJ, Harrison SJ, (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969.
10. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
11. Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, et al. (2011) CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status. Breast Cancer Res Treat 130: 365-375.
12. Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP, (2010) The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 9: 2663-2673.
13. Gould JJ, Kenney PA, Rieger-Christ KM, Silva Neto B, Wszolek MF, et al. (2010) Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol 183: 2395-2402.
14. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, et al. (2010) Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 21: 109-113.
15. Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, et al. (2011) Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 71: 3912-3920.
16. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, et al. (2011) HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or-resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 17: 3219-3232.
17. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, et al. (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835.
18. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PBS Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochemical Pharmacology.
19. Zhang CZ, Chen GG, Merchant JL, Lai PB, (2012) Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma. Cell Cycle 11: 322-334.
20. Chen T, Li M, Zhang R, Wang H, (2009) Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 13: 1358-1370.
21. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, et al. (2010) Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 80: 22-30.
22. Zhang CZ, Zhang HT, Chen GG, Lai PB, (2011) Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis 16: 683-695.
23. Wagner S, Roemer K, (2005) Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf. Biochem Pharmacol 69: 1059-1067.
24. Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, et al. (2008) Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 7: 3285-3297.
25. Dalgard CL, Van Quill KR, O'Brien JM, (2008) Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 14: 3113-3123.
26. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, et al. (2009) Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284: 2203-2213.
27. Ehses JA, Pelech SL, Pederson RA, McIntosh CH, (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277: 37088-37097.
28. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B, (2004) Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64: 7117-7126.
29. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR, (2009) trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis. Biochem Pharmacol 77: 337-347.
30. Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, et al. (2006) IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J Immunol 177: 4064-4071.
31. Sawatzky DA, Willoughby DA, Colville-Nash PR, Rossi AG, (2006) The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo. Am J Pathol 168: 33-41.
32. Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, et al. (2009) EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Clin Cancer Res 15: 4904-4914.
33. Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, et al. (2012) Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. Clin Cancer Res 18: 380-391.
34. Reeves MB, Breidenstein A, Compton T, (2012) Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci U S A 109: 588-593.
35. Calvino E, Estan MC, Simon GP, Sancho P, Boyano-Adanez Mdel C, et al. (2011) Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation. Biochem Pharmacol 82: 1619-1629.
36. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, et al. (2011) MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia.
37. Booy EP, Henson ES, Gibson SB, (2011) Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 30: 2367-2378.
38. Li D, Marchenko ND, Moll UM, (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18: 1904-1913.